Our high throughput, nontargeted approach to small molecule biomarker profiling provides an unprecedented view into the factors that modulate health, disease, and drug response across individuals. These dynamic markers are needed to more effectively align biological targets, patients, and therapies.
metabolites and lipids measured per biosample
biosamples can be analyzed per day
The vast majority of biomarker discovery to date has focused on genomics, yet >80% of disease risk is non-genetic – stemming from internal and external exposures over time – and still largely unexplored.
Sapient’s platform finally enables large-scale profiling of small molecule biomarkers, which read out these dynamic factors, to improve disease understanding and in turn, the precision and efficacy of treatments.
Biomarkers discovered in your samples can be rapidly cross-validated in independent populations within our expansive, in-house Human Biology Database to build confidence in their biological relevance. We can also begin by mining the database for key insights such as identifying potential new drug targets.
biosample datasets collected from diverse individuals
phenotypic data points linked to spectral data
Sapient is a high complexity CLIA-certified, CAP-accredited laboratory, which means we can support rapid translation of the biomarker discoveries we make to regulated clinical applications.
After we identify biomarkers of interest through initial rLC-MS discovery screening, we can use more traditional targeted methods to develop specific metabolites into clinical assays for use in CLIA settings, and can perform and deliver the test results under CLIA.
Whether applied in early research, preclinical, or clinical studies, learn how discovery metabolomics and lipidomics can provide new biological insights to propel your programs forward.